All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results Terminated | 2005-003436-21 | A phase 2, multi-centre, randomised, double blind, placebo controlled study evaluating the efficacy, safety and pharmacokinetics of two doses of a candidate Disease Modifying Anti-Rheumatic Drug (DMAR... | 2008-04-30 | due-trials |
| Reported results | 2006-003730-15 | A 10-week randomised, double-blind, parallel-group, placebo-controlled phase 2 study to investigate the extent of symptom relief and the safety and tolerability of SMP-986 (20 mg, 40 mg, 80 mg and 120... | 2008-06-05 | due-trials |
| Reported results | 2007-003819-31 | A Phase 3 Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of Three Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia | 2010-10-31 | due-trials |
| Completed, but no date, and reported results | 2007-003820-40 | A Phase 3 Randomized, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients with Schizophrenia | bad-data | |
| Completed, but no date, and reported results | 2008-003984-38 | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE COMPARATOR CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF TWO DOSES OF LURASIDONE IN ACUTELY PSYCHOTIC SUBJECTS WITH SCHIZOPHRENI... | bad-data | |
| Reported results | 2008-007457-13 | A Randomized, 6-Week, Double-Blind, Placebo-controlled, Fixed-Flexible-Dose, Parallel-Group Study of Lurasidone in the Treatment of Bipolar I Depression | 2012-02-14 | due-trials |
| Reported results | 2008-007482-23 | A Randomized, 6-Week, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel- Group Study of Lurasidone Adjunctive to Lithium or Divalproex for the Treatment of Bipolar I Depression | 2012-01-19 | due-trials |
| Reported results | 2008-007483-42 | A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression | 2013-02-19 | due-trials |
| Reported results | 2009-012675-10 | An exploratory, randomised, double blind, placebo controlled, 14 day, two-way crossover, inhaled allergen challenge study to evaluate the effects of SMP-028 in subjects with mild to moderate asthma | 2010-06-11 | due-trials |
| Reported results | 2013-003038-34 | A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression | 2017-02-16 | due-trials |
| Reported results | 2013-003039-31 | A Long-Term Study of SM-13496 in Patients with Bipolar I Disorder | 2018-02-17 | due-trials |
| Reported results | 2016-001627-31 | A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC) | 2021-05-06 | due-trials |
| Reported results | 2016-004359-57 | A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma. | 2020-03-29 | due-trials |
| Not reported | 2019-004753-87 | A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols | 2021-05-05 | due-trials |